Description

d[Cha4]-AVP TFA is a potent and selective vasopressin (AVP) V1b receptor agonist with a Ki of 1.2 nM for human V1b receptor. d[Cha4]-AVP TFA shows more selective for V1b receptor than human V1a receptor, V2 receptor, and oxytocin receptors[1][2].—Neuroscience-Neuromodulation–C50H71N13O11S2.xC2HF3O2—-[1]Cristiana Griffante, et al. Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist. Br J Pharmacol. 2005 Nov;146(5):744-51.|[2]Ling Ling Cheng, et al. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.—-N/A—-O=C(N1[C@H](C(N[C@@H](CCCNC(N)=N)C(NCC(N)=O)=O)=O)CCC1)[C@H]2NC([C@H](CC(N)=O)NC([C@H](CC3CCCCC3)NC([C@H](CC4=CC=CC=C4)NC([C@H](CC5=CC=C(O)C=C5)NC(CCSSC2)=O)=O)=O)=O)=O.O=C(O)C(F)(F)F.[x]–Endocrinology–10 mM in DMSO–Vasopressin Receptor–V1b Receptor –GPCR/G Protein–Peptides